Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 18,408 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of RGLS8429 in Healthy Volunteers

NCT05429073
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RGLS8429, Placebo volume-matching RGLS8429 dose
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of an Oral Hair Supplement to Improve Hair Strength and Support Growth in Women and Men

NCT06362941
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Women's Hair Growth Supplemnt, Nutrafol Women's Balance Hair Growth Supplement, Nutrafol Women's Vegan Hair Growth Supplement, Nutrafol Women's Postpartum Hair Growth Supplement, Nutrafol Men's Hair Growth Supplement
Dietary Supplement
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 28, 2026, 5:26 PM EDT
Recruiting Not applicable Interventional

CAPABLE Transplant

NCT06326905
View directory record Official record
Conditions
Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Interventions
CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

NCT01354431
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
34
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Oct 28, 2026, 5:26 PM EDT
Completed No phase listed Observational

Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension

NCT04402645
View directory record Official record
Conditions
Pulmonary Hypertension, Infant, Premature
Interventions
Not listed
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
14 Days and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

MyVoice:Rheum Decision Aid for Women With Rheumatic Diseases

NCT04879745
View directory record Official record
Conditions
Rheumatic Diseases, Physician-Patient Relations, Contraception
Interventions
MyVoice:Rheum, Pamphlet
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

NCT01070979
View directory record Official record
Conditions
Hormone Replacement Therapy
Interventions
Estradiol acetate, Estradiol, Conjugated equine estrogens
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
32
States / cities
Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

NCT00376896
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
GW876008 200mcg, GW876008 20mcg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 28, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

[18F]FES PET/.CT in Uterine Cancer

NCT05916196
View directory record Official record
Conditions
Uterine Cancer
Interventions
18F-Fluoroestradiol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 5:26 PM EDT
Completed No phase listed Observational

Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer

NCT00898703
View directory record Official record
Conditions
Breast Cancer
Interventions
flow cytometry, immunoenzyme technique, laboratory biomarker analysis
Other
Lead sponsor
University of Arizona
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Oct 28, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test

NCT00682851
View directory record Official record
Conditions
Bacterial Vaginosis, Urogenital Infection by Trichomonas Vaginalis
Interventions
OSOM Trichomonas Rapid Test, OSOM BVBlue Test
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
15 Years and older · Female only
Enrollment
519 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Tisotumab Vedotin in Cervical Cancer

NCT03438396
View directory record Official record
Conditions
Cervical Cancer
Interventions
tisotumab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 28, 2026, 5:26 PM EDT
Terminated Not applicable Interventional

Home Biofeedback or Pelvic Floor Physical Therapy for Postpartum Urinary Incontinence.

NCT05194462
View directory record Official record
Conditions
Urinary Incontinence, Pelvic Floor Disorders
Interventions
Pericoach® by Analytica, Pelvic Floor Physical Therapy
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Monroeville, Pennsylvania • Pittsburgh, Pennsylvania • Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 28, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational

Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer

NCT04569773
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Impact of Event Scale-Revised, Reproductive Concerns Scale, Decision Regret Scale
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT01720173
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Dalantercept, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Fort Collins, Colorado • Hartford, Connecticut • New Britain, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 28, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Preventing Sickle Cell Kidney Disease

NCT02373241
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions
Losartan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 28, 2026, 5:26 PM EDT
Recruiting Not applicable Interventional

Clinical Study of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis (VVC)

NCT06983041
View directory record Official record
Conditions
Vulvovaginal Candidiasis (VVC), Yeast Vaginitis
Interventions
vaginal cooling device
Device
Lead sponsor
Coologics, Inc
Industry
Eligibility
22 Years to 49 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
Jacksonville, Florida • Miami, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

NCT00470366
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
pegfilgrastim, cisplatin, ifosfamide, paclitaxel
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Monitoring Physical Activity in Hispanic Women With Chronic Neurological Disorders

NCT04820153
View directory record Official record
Conditions
Neurological Disorder
Interventions
Physical Activity Monitoring Device, Lifestyle Redesign Coaching
Device · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
30 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 28, 2026, 5:26 PM EDT
Terminated Phase 4 Interventional Results available

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

NCT02035345
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer
Interventions
Carboplatin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 28, 2026, 5:26 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

NCT02245945
View directory record Official record
Conditions
HIV Prevention
Interventions
TFV 1% vaginal gel, HEC Placebo Gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
15 Years to 17 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
The Bronx, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NEM® + BIOCURC® Versus Placebo in Exercised-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy Men & Women

NCT03769857
View directory record Official record
Conditions
Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Joint Cartilage Turnover
Interventions
NEM® + BIOCURC®, Placebo
Dietary Supplement
Lead sponsor
ESM Technologies, LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 28, 2026, 5:26 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Preop Video on Patient Anxiety

NCT05633901
View directory record Official record
Conditions
Prolapse, Vaginal, Prolapse, Uterine, Prolapse; Female
Interventions
Educational Video, Standard Counseling
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 28, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Results available

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

NCT00823303
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Paricalcitol, Calcitriol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 28, 2026, 5:26 PM EDT